Pursuant to our prior intimation dated April 15, 2026 and deferment intimation dated April 20, 2026, and in terms of Regulation 30 of the Securities and Exchange Board of India (Listing ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
iSERA Lifesciences Limited (formerly Covidh Technologies Limited) held a Board meeting on April 21, 2026 approving several key matters. The company will increase its authorised share capital from Rs. 11 crore to Rs. 25 crore by creating 1.4 crore additional equity shares. The Board approved the acquisition of 100% stake in iSERA Biological Limited through a share swap arrangement valued at Rs. 78.01 crore. Under this deal, the company will issue 1,61,82,800 equity shares at Rs. 48.20 per share (1:1 swap ratio) to shareholders of iSERA Biological Limited. The target company had turnover of Rs. 18.36 crore in FY 2024-25 with EBITDA of Rs. 7.67 crore, operating in the pharmaceutical and biotechnology sector. This is a related party transaction as promoters of iSERA Lifesciences are also shareholders of iSERA Biological Limited. All approvals are subject to shareholder nod via postal ballot and BSE in-principle approval.
The acquisition will make iSERA Biological Limited a wholly-owned subsidiary, expanding the company's pharmaceutical and life sciences presence. Existing shareholders will see dilution as 1.62 crore new shares are issued, with promoter group holding increasing significantly post-transaction.